Table 4.

Small molecule TRPC1, C4, C5 antagonists.

Namea	Structure	Target	Concentration or IC50	Reference
ML204		TRPC4 TRPC5	IC50, 0.96 μM	Miller et al., 2011
M084		TRPC4 TRPC5	IC50, 10.3 μM IC50, 8.2 μM	Zhu et al., 2015
HC-070		TRPC4 TRPC5 TRPC4–C1 TRPC5–C1	IC50, 46 nM IC50, 9.3 nM	Just et al., 2018
HC-608 (Pico145)		TRPC4 TRPC5 TRPC4–C1 TRPC5–C1	IC50, 32.5 nM IC50, 6.2 nM 9 – 1,300 pM	Just et al., 2018; Rubaiy et al., 2017
AC1903		TRPC5	IC50, 14.7 μM	Zhou et al., 2017
Clemizole		TRPC4β TRPC5	IC50, 6.4 μM IC50, 1.0–1.3 μM	Richter et al., 2014a
GFB-887	Not disclosed	TRPC5	IC50, 11 nM	Mundel et al., 2019
A54		A498 cells TRPC1–C4	IC50, 62 nM	Rubaiy et al., 2018b
[6]-shogaol		TRPC5	IC50, 18.3 μM	Kim et al., 2016
Galangin		TRPC5	IC50, 0.45 μM	Naylor et al., 2016
Kaempferol		TRPC5	IC50, 3.9 μM	Naylor et al., 2016
Quercetin		TRPC5	IC50, 6.5 μM	Naylor et al., 2016
AM12		TRPC5 TRPC4	IC50, 0.28 μM	Naylor et al., 2016
Chlorogenic acid (CGA)		Suppressed TRPC1 expression	300 μM	Jung et al., 2017
Spironolactone		Suppressed TRPC1, C6 expression	3 mg/kg body weight/day (in vivo)	Li et al., 2017
Topotecan (TPT),		Suppressed expression of TRPC1, C4	IC50, 1–10 nM	Jiang et al., 2018
Rosiglitazone (RSG)		Reduced TRPC1 activation	IC50, 10 μM	Wei et al., 2017
Apigenin		TRPC5	IC50 >>10 μM	Naylor et al., 2016

^aCompounds with selectivity information and likelihood of direct interaction with the channel are highlighted in bold letters and shaded rows.